Literature DB >> 29496697

MRD negativity as a surrogate for PFS in CLL?

Philip A Thompson1.   

Abstract

Mesh:

Substances:

Year:  2018        PMID: 29496697     DOI: 10.1182/blood-2018-01-824177

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  5 in total

1.  Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.

Authors:  Xin Victoria Wang; Curtis A Hanson; Renee C Tschumper; Connie E Lesnick; Esteban Braggio; Elisabeth M Paietta; Susan O'Brien; Jacqueline C Barrientos; Jose Francisco Leis; Cong Christine Zhang; Steven E Coutre; Paul M Barr; Amanda F Cashen; Anthony R Mato; Avina K Singh; Michael P Mullane; Harry Erba; Richard Stone; Mark R Litzow; Martin S Tallman; Tait D Shanafelt; Neil E Kay
Journal:  Blood       Date:  2021-12-30       Impact factor: 25.476

2.  Measurable residual disease testing in chronic lymphocytic leukaemia: hype, hope neither or both?

Authors:  Shenmiao Yang; Neil E Kay; Min Shi; Gert Ossenkoppele; Roland B Walter; Robert Peter Gale
Journal:  Leukemia       Date:  2021-09-27       Impact factor: 11.528

Review 3.  Frontline therapies for untreated chronic lymphoid leukemia.

Authors:  Delong Liu; Juanjuan Zhao
Journal:  Exp Hematol Oncol       Date:  2019-08-17

4.  Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry.

Authors:  Ferenc Takács; Lili Kotmayer; Ágnes Czeti; Gábor Szalóki; Tamás László; Gábor Mikala; Ágnes Márk; András Masszi; Péter Farkas; Márk Plander; Júlia Weisinger; Judit Demeter; Sándor Fekete; László Szerafin; Beáta Margit Deák; Erika Szaleczky; Adrienn Sulák; Zita Borbényi; Gábor Barna
Journal:  Pathol Oncol Res       Date:  2022-09-21       Impact factor: 2.874

Review 5.  Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?

Authors:  Moritz Fürstenau; Nisha De Silva; Barbara Eichhorst; Michael Hallek
Journal:  Hemasphere       Date:  2019-08-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.